Hologic (HOLX) Rating Increased to Conviction-Buy at Goldman Sachs Group

Hologic (NASDAQ:HOLX) was upgraded by Goldman Sachs Group from a “buy” rating to a “conviction-buy” rating in a research report issued on Friday. The firm currently has a $50.00 target price on the medical equipment provider’s stock, up from their previous target price of $45.00. Goldman Sachs Group’s price objective would indicate a potential upside of 17.12% from the stock’s current price.

A number of other research analysts have also recently issued reports on HOLX. Needham & Company LLC reaffirmed a “buy” rating and set a $48.00 price objective (up from $46.00) on shares of Hologic in a research note on Tuesday, December 5th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $42.00 price objective on shares of Hologic in a research note on Friday, September 22nd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $48.00 price objective on shares of Hologic in a research note on Thursday, November 9th. Jefferies Group reaffirmed a “buy” rating and set a $44.00 price objective (down from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. Finally, Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $47.62.

Hologic (NASDAQ:HOLX) opened at $42.69 on Friday. The company has a market capitalization of $11,770.00, a price-to-earnings ratio of 20.63, a P/E/G ratio of 2.02 and a beta of 0.95. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic has a 12 month low of $35.76 and a 12 month high of $46.80.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. During the same period last year, the firm earned $0.52 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. equities analysts forecast that Hologic will post 2.12 EPS for the current year.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Insiders sold 28,833 shares of company stock worth $1,107,270 over the last three months. 0.79% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Parnassus Investments CA purchased a new stake in Hologic in the third quarter worth about $277,062,000. Capital World Investors purchased a new stake in Hologic in the second quarter worth about $312,441,000. HealthCor Management L.P. purchased a new stake in Hologic in the second quarter worth about $76,604,000. Columbus Circle Investors purchased a new stake in Hologic in the second quarter worth about $54,511,000. Finally, Vanguard Group Inc. lifted its holdings in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after buying an additional 1,200,825 shares during the period. 98.09% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Hologic (HOLX) Rating Increased to Conviction-Buy at Goldman Sachs Group” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://transcriptdaily.com/2017/12/10/hologic-holx-rating-increased-to-conviction-buy-at-goldman-sachs-group.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply